BIOLASE, Inc. (NasdaqCM:BIOL) has filed a shelf registration in the amount of $12.50 million. BIOLASE anticipates using the net proceeds from the sale of securities to fund general and administrative expenses. BIOLASE may also use a portion of the net proceeds to pay off outstanding indebtedness and/or acquire or invest in complementary businesses, products and technologies.

BIOLASE evaluates acquisition opportunities and engage in related discussions with other companies from time to time. Pending the use of the net proceeds, BIOLASE intends to invest the net proceeds in short-term, interest-bearing, investment-grade securities.